Description
Diabetic peripheral neuropathy is one of the most common and debilitating complications of long-standing diabetes, significantly impacting patients’ quality of life. This webinar will delve into the mechanisms behind nerve damage, early warning signs, and the clinical tools required for accurate diagnosis. Participants will gain insights into risk stratification, preventive strategies, and evidence-based management approaches to slow progression and relieve symptoms. The session will also highlight the importance of multidisciplinary care, patient education, and lifestyle interventions in improving outcomes. Designed for healthcare professionals, this discussion provides a comprehensive understanding of neuropathy in the context of diabetes care.
Summary Listen
- Diabetic peripheral neuropathy (DPN) results from nerve fiber damage in the peripheral nervous system due to diabetes, specifically affecting somatic nerves. The most common type is chronic insidious sensory neuropathy, characterized by progressive pain, hypersensitivity, muscle wasting, and autonomic dysfunction in the legs and feet. Other types include acute painful neuropathy (sudden, unilateral pain), diffuse motor neuropathy (generalized muscle wasting and weakness), and focal neuropathy (pressure or vascular damage to specific nerves).
- The risk of DPN increases significantly over time in diabetic patients, with nearly half developing neuropathy after 10 years. Diagnosis is primarily clinical, based on symptoms like pain and paresthesia, and supported by electrodiagnostic testing. DPN is associated with high rates of disability, foot ulcers, amputations, and reduced quality of life, including anxiety, depression, and sleep disturbances.
- Hyperglycemia triggers biochemical changes, including the activation of polyol pathways, accumulation of advanced glycation end products (AGEs), and increased production of free radicals. These mechanisms contribute to structural nerve damage, making DPN both a neurological and vascular disease. The pain associated with DPN can be nociceptive (aching, throbbing) or neuropathic (tingling, shooting, burning), with neuropathic pain being more challenging to treat.
- Clinical examinations for DPN involve assessing sensory perception (vibration, position, temperature, light touch, and pain), deep tendon reflexes (ankle and knee), and motor function (muscle strength and atrophy). Diagnostic tools include monofilament testing (sensitivity), brush tests (mechanical allodynia), pain-prick tests (hyperalgesia/hypoalgesia), hot/cold tests (thermal allodynia), vibration tests (large nerve fibers), quantitative sensory testing (action potential levels), and nerve conduction velocity studies (nerve damage extent).
- Management of DPN involves excluding non-diabetic etiologies and achieving optimal glycemic and metabolic control. First-line pharmacological treatments include anticonvulsants (gabapentin, pregabalin) and antidepressants (amitriptyline, duloxetine). Second-line options consist of opioids. Topical treatments (nitrate sprays, capsaicin) and transcutaneous electrical nerve stimulation (TENS) can also be used.
- Treatment goals for DPN focus on achieving a realistic 50% pain relief, which can improve sleep, mood, nerve function, and overall quality of life. Early, aggressive interventions to control blood sugar and address modifiable cardiovascular risk factors are crucial for preventing or reversing nerve damage.
Sample Certificate
About the Speakers
Dr. Sumon Chowdhary
Endocrinologist, Chittagong Diabetic General Hospital, Bangladesh
Financial Disclosure
Comments
Comments
You must be logged in to leave a comment.